News for Crescita Therapeutics Inc. (CRRTF)

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (”œCrescita” or the ”œCompany”), a growth-oriented, innovation-driven Canadian commercial dermato

Crescita Therapeutics has mutually terminated its licensing agreement with Croma Pharma GmbH for Pliaglis®. Croma will pay Crescita €575,000 (approxi

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (”œCrescita” or the ”œCompany”), a growth-oriented, innovation-driven Canadian commercial dermato

Crescita Therapeutics Inc. (TSX: CTX, OTC: CRRTF) reported a Q1 2025 revenue decline of 29.2% compared to Q1 2024. Net loss increased to $932,000 in Q1

Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (”œCrescita” or the ”œCompany”), a growth-oriented, innovation-driven Canadian commercial dermato

LAVAL, Quebec — Crescita Therapeutics Inc. (

LAVAL, Quebec — Crescita Therapeutics Inc. (

LAVAL, Quebec — Crescita Therapeutics Inc. (

LAVAL, Quebec — Crescita Therapeutics Inc. (

Crescita Therapeutics Inc. , a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of...

LAVAL, Quebec — Crescita Therapeutics Inc. (

LAVAL, Quebec — Crescita Therapeutics Inc. (

Crescita Therapeutics Inc. , a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December...

LAVAL, Quebec — Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“

/PRNewswire/ -- Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch...